Side-Branch Bifurcation Stent Earns CE Stamp of Approval
February 7, 2008 - Tryton Medical Inc.’s Side Branch Stent obtains CE Mark approval based on results in the Tryton 1 (First-in-Man Study) with No Side-Branch Restenosis in 30 patients, according to the manufacturer.
The Tryton Side-Branch Stent is a cobalt chromium balloon-expandable coronary stent specifically developed for the complete treatment of the entire spectrum of coronary artery bifurcation disease.
The results of the Tryton 1 (First-In-Man) Study were presented by Profesor Patrick Serruys, Erasmus University/Thoraxcenter, and Ralf Müller, M.D., Helios Heart Centrum. When the Tryton cobalt chromium Bare Metal Stent was used with a standard drug eluting stent, no side branch restenosis was observed in the 30 patients treated. The initial core laboratory quantitative analysis reported a late loss of 0.27 /- 0.42 mm in the side branch and 0.12 /- 0.47 mm in the main vessel.
“This technology has the capacity to redefine the treatment of bifurcation lesions and resolve a frequent dilemma of the interventional cardiologist,” said Professor Patrick W. J. C. Serruys, M.D., head of the Department of Interventional Cardiology, Thoraxcenter, Erasmus Medical Center, Rotterdam, the Netherlands.
For more information: www.TrytonMedical.com
More like this
- Tryton Medical Launches CE Mark Stent System for Bifurcation Lesions
- Tryton Medical Receives CE Mark Approval for its Side-Branch Stent
- Bifurcation Stent Now Used in 750 Patients
- Bifurcation Stent Study Enrollment Completed for Two European Registries
- Tryton Celebrates 250th Implant of its Side Branch Stent System